Standing out in a crowded field: How Temedica's two-sided business model sets it apart

Plenty of companies claim to have a foothold in the fast-growing areas of digital health and real-world evidence.

But what Germany-based Temedica is doing across both fields makes it unique and of interest to a range of players in healthcare including patients, investors and pharma companies.

"Our aim is to enable personalized medicine in the future"Gloria Seibert, the company’s chief executive, who set up Temedica in 2016, said: “Our mission is to craft the future of personal health. What we mean by that is that we want to build a solid understanding about how patients really are, and how therapies are really impacting a patient’s health. We believe that personalized medicine is only possible when everyone in the life sciences industry has a solid understanding of the patient, because otherwise you cannot put a personalized therapy to the patient.